Abstract
GENERAL COMMENTARY article Front. Immunol., 07 January 2013Sec. Vaccines and Molecular Therapeutics Volume 3 - 2012 | https://doi.org/10.3389/fimmu.2012.00409
Highlights
Alessandro Ottaiano 1*, Maurizio Capuozzo 2, Guglielmo Nasti 1, Piera Maiolino 3, Valentina De Angelis 4, Stefania Scala 5 and Rosario V
Randomized trials with anti-Epidermal Growth Factor Receptor (EGFR) antibodies have shown a significant impact of KRAS [wild type vs. mutated] on response and prognosis: the presence of KRAS activating mutations was found to be associated with reduced biological and clinical activity for the treatment
Both antibody-dependent cell-mediated cytotoxicity (ADCC) and cetuximabinduced macrophage responses can be more pronounced for FcγRIIIa 158-Val carriers (Tsuchiya et al, 2007; Pander et al, 2011)
Summary
Alessandro Ottaiano 1*, Maurizio Capuozzo 2, Guglielmo Nasti 1, Piera Maiolino 3, Valentina De Angelis 4, Stefania Scala 5 and Rosario V. The evolving role of monoclonal antibodies in colorectal cancer: early presumptions and impact on clinical trial development by Eng, C. One of the most successfully approach in the treatment of metastatic colorectal cancer (mCRC) is the inhibition of the Epidermal Growth Factor Receptor (EGFR) pathway by antibodies (cetuximab and panitumumab).
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call